LOWELL, Mass., Jan. 8, 2014 /PRNewswire/ –InfoBionic’, an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced receipt of CE Mark for the MoMe’ System for cardiac arrhythmia monitoring. The MoMe System is the first universal remote patient monitoring platform with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes. The innovative platform, which leverages Cloud computing and proprietary analytics, is poised to revolutionize the $3B worldwide cardiac monitoring market by delivering on-demand access to patient data for diagnosis.

The MoMe System draws on the recent convergence of medical devices, database analytics, new sensors, and wireless protocols to provide a universal patient monitoring platform complete with real-time, high-quality patient data for improved arrhythmia detection.

“Existing cardiac patient monitoring systems have significant limitations, including poor data quality and limited data availability,” stated Liviu Klein, M.D., UCSF Heart and Vascular Center. “The MoMe System provides high-quality data and real-time rhythm history as well as activity, respiration and symptom tracking that allows me to make a fast, accurate, timely and efficient medical diagnosis.”

Nancy Briefs, Chief Executive Officer, commented, “We are pleased to receive CE Mark for the MoMe System. We believe the system will transform the arrhythmia monitoring market by offering superior arrhythmia detection and favorable physician practice economics. We look forward to commercializing our first product for cardiac arrhythmia monitoring in early 2014.”

About InfoBionic:

InfoBionic’ Inc., an emerging digital health company is dedicated to transforming healthcare delivery by providing anywhere, anytime access to cardiac event monitoring with improved event detection and clinical efficacy through a lower cost business model. The MoMe’ System offers superior remote patient monitoring for chronic diseases with an initial market focus on cardiac arrhythmias.

For more information please visit www.infobionic.com.

SOURCE InfoBionic Inc.

Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business, is proud to announce it will co-sponsor the 2014 Massachusetts Medical Device Development (M2D2) Center’s New Venture Competition. Designed to showcase innovative ideas coming out of early-stage medical device companies, the nationwide competition this year will focus on Joint Reconstruction, Sports Medicine, and Trauma.

The prizes will total $50,000 of in-kind services including facilities, engineering, legal, business and medical device assistance from Smith & Nephew and the competition co-sponsors, Nutter McClennen & Fish LLP and M2D2, a joint initiative of the University of Massachusetts’ Lowell and Worcester campuses.

‘We’re excited about this collaboration,’ explains Dr. Ruth Cheng, Director of Innovation for Smith & Nephew. ‘Not only does it build on our reputation as innovation leaders; it helps us foster relationships with those entrepreneurs who are on the cutting edge of the growth areas we target.’

‘M2D2 is grateful for the Smith & Nephew’s support for the New Venture Competition and entrepreneurs and startups in the medical-device sector,’ said Steven Tello, UMass Lowell’s associate vice chancellor for entrepreneurship and economic development. ‘We are honored to work with a company that exemplifies success in the industry in Massachusetts and around the globe.’

For the competition, Smith & Nephew has identified five areas where innovation will help address current and future needs in orthopaedic reconstruction, sports medicine, and trauma:

• Tools which enable procedure
  simplification: Solutions
  would reduce procedural steps, shorten overall procedure time, provide
  surgeons with greater confidence, and/or ensure consistency from procedure
  to procedure.
• Tissue sparing procedures: Solutions would shorten recovery time,
  decrease the incision/number of portals, and/or reduce bone removal/soft
  tissue damage, and/or minimize potential for human error.
• Stabilization of and integration/fixation
  to bone: Solutions would
  provide high fixation strength both immediately and long-term, and work
  regardless of bone density.
• Novel soft tissue repair: Solutions would provide or restore the
  alignment and functionality of the target tissue immediately and long
  term, and be minimally invasive.
• Joint preservation solutions: Solutions would provide effective
  protection of joints, and be minimally invasive. Solution can be either
  short-term or long-term/permanent. Early intervention solutions preferred.

All applicants must submit an initial application which will be reviewed by M2D2. Fifteen finalists will then be invited to present their concepts in-person at a public event at M2D2’s offices on March 26, 2014.

For more information on the competition and how to apply, companies should visit www.uml.edu/M2D2.